Bcb-276

Phase 2

BBrainChild Bio, Inc

Bcb-276 is one of 17 therapeutic programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diffuse Intrinsic Pontine GliomaRecruiting

Diffuse Intrinsic Pontine GliomaPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Diffuse Intrinsic Pontine Glioma

#DrugCompanyPhaseTrials

Verzenio

Eli Lilly

Approved

—2

Caprelsa

GGenzyme, a Sanofi Company

Approved

—3

Aldara

BBausch Health Americas, Inc.

Farydak

Avastin

4 6

Adriamycin

Pfizer

Phase 2

2 7

ONC201

Jazz Pharmaceuticals

Phase 3

3 8

Rituxan

Roche

Phase 1

1 9

Fludara

Sanofi

Phase 1

1 10

Paxalisib

KKazia Therapeutics Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Recruiting

Diffuse Intrinsic Pontine Glioma

NCT07680439

Clinical

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma1 trial

A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma

Recruiting·BBrainChild Bio, Inc·Phase 2·NCT07680439·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bcb-276. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bcb-276. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — BrainChild Bio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBrainChild Bio, Inc

Bcb-276

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma1 trial

References

Drug Info

Quick Facts

Related News